Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 20/20 | 1.00 |
| ▸ | ICAM1 | P05362 | 20/20 | 1.00 |
| ▸ | ITGAL | P20701 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4242841 | 1.00 | ITGB2 (1.00) | ITGB2ICAM1ITGAL | |
| SCHEMBL13817194 | 0.91 | ITGB2 (0.84) | ITGB2ICAM1ITGAL | |
| SCHEMBL13817008 | 0.90 | ITGB2 (1.00) | ITGB2ICAM1ITGAL | |
| SCHEMBL2394410 | 0.89 | ITGB2 (1.00) | ITGB2ICAM1ITGAL | |
| SCHEMBL2394405 | 0.89 | ITGB2 (1.00) | ITGB2ICAM1ITGAL | |
| SCHEMBL13817007 | 0.87 | ITGB2 (0.77) | ITGB2ICAM1ITGAL | |
| SCHEMBL13817004 | 0.87 | ITGB2 (0.77) | ITGB2ICAM1ITGAL | |
| SCHEMBL13817172 | 0.87 | ITGB2 (0.77) | ITGB2ICAM1ITGAL | |
| SCHEMBL2392816 | 0.86 | ITGB2 (0.85) | ITGB2ICAM1ITGAL | |
| SCHEMBL2392809 | 0.86 | ITGB2 (0.85) | ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550494-B2 | Small molecules useful in the treatment of inflammatory disease | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550494-B2 | Small molecules useful in the treatment of inflammatory disease | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20090088571-A1 | Synthesis of 6,7-Dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonic acid amides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-02 | — | — | US | disclosed |
| US-20090088571-A1 | Synthesis of 6,7-Dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonic acid amides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-02 | — | — | US | disclosed |
| US-20090088571-A1 | Synthesis of 6,7-Dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonic acid amides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-02 | — | — | US | disclosed |
| US-7470795-B2 | Synthesis of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonic acid amides | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470795-B2 | Synthesis of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonic acid amides | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470795-B2 | Synthesis of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonic acid amides | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| EP-1216247-B1 | IMIDAZOIMIDAZOLES AND TRIAZOLES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMA (US) | 2008-11-05 | — | — | EP | disclosed |
| EP-1776367-A1 | SYNTHESIS OF 6,7-DIHYDRO-5H-IMIDAZOÝ1,2-A¨IMIDAZOLE-3-SULFONIC ACID AMIDES | Boehringer Ingelheim International GmbH (DE) | 2007-04-25 | — | — | EP | disclosed |
| WO-2006014828-A1 | SYNTHESIS OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-A]IMIDAZOLE-3-SULFONIC ACID AMIDES | BOEHRINGER INGELHEIM INTERNATIONAL, GMBH (DE) | 2006-02-09 | — | — | WO | disclosed |
| US-20060025447-A1 | Synthesis of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonic acid amides | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025447-A1 | Synthesis of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonic acid amides | ICAM1, CD14, VCAM1 | ITGB2 125/4885ICAM1 1/4885ITGAL 33/4885 |
| US-20090088571-A1 | Synthesis of 6,7-Dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonic acid amides | ICAM1, CD14, VCAM1 | ITGB2 125/4885ICAM1 1/4885ITGAL 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.